This study is being conducted to evaluate the safety and efficacy of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
ClinicalTrialDisclosure@JazzPharma.com
Part A and Part B are double-blind treatment phases followed by a 52-week open label extension.
Participants with JME will be randomized to JZP926 capsule based on weight-tiered dosing for a 16-week treatment period.
Participants with JME will be randomized to matching placebo based on weight-tiered dosing for a 16-week treatment period.
Participants completing Part A or Part B will have the option to continue into an open-label extension for up to 52 weeks, inclusive of a 4 week blinded transition.
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.
A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy
A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension